Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXPBiotechnology
-$0.24 today
- Market cap
- $54.80M
- Beta
- 1.68
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$10.75
Volume 1.04M
Average 0.49M
TNXP Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $2.13M rose 126.2% year over year, ahead of the +18.0% change in trailing-twelve-month cost of revenue. Sequentially, it rose 38.0% from the prior quarter.
Context
- Cost of revenue amounted to 65.3% of revenue in FY2025, down 11.6 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +126.2% holds above the trailing-twelve-month pace of +18.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 8.57M USD
- Year-over-year change
- +10.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.57M | +10.3% |
| FY2024 | 2024-12-31 | 7.77M | +63.8% |
| FY2023 | 2023-12-31 | 4.74M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How TNXP compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +18.0% is the 2nd highest of 7, against a peer median of -80.6%.
- Cost of revenue amounts to 47.4% of revenue for TNXP, versus a peer median of 120.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.58M USD | -62.0% | -2.1% | 515.8% | |
| LTM Mar 2026 | $10.68M USD | +89.7% | — | 18096.6% | |
| LTM Mar 2026 | $8.32M USD | +18.0% | — | 47.4% | |
| LTM Mar 2026 | $2.34M USD | — | — | — | |
| LTM Mar 2026 | $1.39M USD | -86.2% | — | 120.9% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $289K USD | -75.2% | +2.2% | — |
| LTM Mar 2026 | $95K USD | — | — | 5.3% | |
| LTM Mar 2026 | $6K USD | -86.0% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| FY2025 | €0 EUR | -100.0% | — | 0.0% | |
| Peer median (excluding TNXP) | — | -80.6% | +0.0% | 120.9% | |
Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7.77M | 10.09M | 13.11M |
| Cost of Revenue | 0 | 0 | 4.74M | 7.77M | 8.57M |
| Gross Profit | 0 | 0 | 3.03M | 2.33M | 4.54M |
| Gross Margin | — | — | 39.0% | 23.1% | 34.7% |
| Research & Development | 68.84M | 81.88M | 86.66M | 40.45M | 44.49M |
| Selling, General & Admin | 23.47M | 30.22M | 34.75M | 40.1M | 85.76M |
| Operating Expenses | 92.31M | 112.09M | 121.41M | 139.03M | 130.25M |
| Depreciation & Amortization | 50K | 1.25M | 4.29M | 3.42M | 1.93M |
| EBITDA | (92.24M) | (108.97M) | (112.37M) | (74.32M) | (122.01M) |
| EBITDA Margin | — | — | -1446.5% | -736.3% | -930.9% |
| Operating Income | (92.31M) | (112.09M) | (118.38M) | (136.7M) | (125.7M) |
| Operating Margin | — | — | -1523.9% | -1354.3% | -959.1% |
| Interest Income | 25K | 1.87M | 0 | 0 | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 89K |
| Other Income / Expenses | 25K | 1.87M | 1.72M | 6.67M | 1.68M |
| Income Before Tax | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Pre-Tax Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Net Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| EPS (Basic) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| EPS (Diluted) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| Weighted Avg Shares | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
| Weighted Avg Shares (Diluted) | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.